MARLBOROUGH, Mass.--(BUSINESS WIRE)--Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, announced today that the company has been added to the Russell 2000®, 3000®, Russell Global, and Russell Microcap indices. "We are pleased to be added to these Russell indices, another important milestone in improving our visibility among the investment community," said Paul K. Wotton Ph.D., President and CEO of Ocata Therapeutics, who adde
| < Prev | Next > |
|---|
